Implementation of pharmacogenomics testing for precision medicine.
Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2023 Sep 30; 1-18.
PMID: 37776898
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 Jul; 7:e2300095.
PMID: 37410974
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 09 01; 41(25):4107-4117.
PMID: 37369081
DPYD Testing: Time to Put Patient Safety First.
DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705.
PMID: 36821823
Implementation of pharmacogenomics into inpatient general medicine.
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
PMID: 36729768
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023 03; 34(3):289-299.
PMID: 36494006
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022 11 04; 13(1):6658.
PMID: 36333289
In Reply.
In Reply. Oncologist. 2022 Oct 01; 27(10):e827-e828.
PMID: 36036599
Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System.
Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. J Pers Med. 2022 Jul 15; 12(7).
PMID: 35887642
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
PMID: 35732350